Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by enriquesuave


V.TLT

RE:RE:RE:RE:Very Good News!

I believe Adstiladrin CR rate is 23.5% at 360 days  and probably less at...

December 17, 2022

V.TLT

RE:Very Good News!

In comparison we may very well qualify for AA after data on 40-50 patients...

December 16, 2022

V.TLT

Very Good News!

FDA approves Adstliadrin for NMIBC.  They have 4 instillations ( not bad...

December 16, 2022

V.TLT

RE:Late abstractAUA conference - April 28 to May 1

I remember when Sesen Bio presented their data a few years back on about 40...

December 15, 2022

V.TLT

RE:RE:RE:RE:RE:RE:Is FDA submission material enough for an NR?

No, I never read her book, but I figured she was hired to help prepare...

December 15, 2022

V.TLT

RE:RE:RE:RE:Is FDA submission material enough for an NR?

Im thinking they had hired Vera to prepare this, and now it's just final...

December 15, 2022

V.TLT

Moderna cancer vaccine

Moderna MRNA just added about $15 Billion in Market Cap today on news of a 44...

December 13, 2022

V.TLT

RE:RE:Big Pharma Question for The Resident Experts

There is no pill produced by big Pharma which treats cancer effectively...

December 13, 2022

V.TLT

RE:Accelerated Approval - what are the chances?

Those are CR patients, plus we have PR patients some of which may end up CR...

December 8, 2022

V.TLT

RE:AA requires proof of enrollment

I don't see any problems here.  Clearly laid out in FDA trial...

December 5, 2022

V.TLT

RE:The next several months should be exciting !

Looks like the TLD-3000B will probably be a device capable of creating...

December 4, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CG Oncology NMIBC data

Well said Slayer  No reason not to keep treating PR/ IR patients until...

December 4, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CG Oncology NMIBC data

I would say give 2 treatments to all, and a 3rd for those who are still PR or...

December 3, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:CG Oncology NMIBC data

On top of our best in class single agent data so far, the fact that this a...

December 2, 2022

V.TLT

RE:CG Oncology NMIBC data

We are beating CG0070 so far it seems.  They are at 27-28% CR as single...

December 1, 2022

V.TLT

RE:RE:BioTuesdays by Kilmer Lucas

I agree here .  Not taking into account Accelerated Approval.  TLD...

December 1, 2022

V.TLT

RE:RE:RE:Normally we have a 20% drop!

Well laid out Slayer.  The 30% Benchmark was just a recommendation, but...

November 30, 2022

V.TLT

RE:Normally we have a 20% drop!

We saw the same market reaction after last Q report.  Drop day of report...

November 30, 2022

V.TLT

RE:Enrique and Eoghan : help please

The 1st chart is CR at any time point  23 patients reached CR at 90 days...

November 29, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:BTD application

This high efficacy shows that probably more treatments for those not Cr or PR...

November 29, 2022